Lookup NU author(s): Monique Zangarini,
Professor Gareth Veal
This is the authors' accepted manuscript of an article that has been published in its final definitive form by Future Medicine Ltd., 2017.
For re-use rights please refer to the publisher's terms and conditions.
© 2017 Future Science Ltd. Aim: SRA737 is an orally active small-molecule inhibitor of checkpoint kinase 1 being investigated in an oncology setting. A HPLC-MS/MS method for quantifying plasma concentrations of SRA737 was validated. Methods & results: Sample preparation involved protein precipitation with acetonitrile following addition of 13C15N-deuterated SRA737 as internal standard. A rapid and selective method was fully validated across a range of 5-20,000 ng/ml, exhibiting good sensitivity, overall precision (expressed as coefficient of variation) ≤8.0% and accuracy 96-102%. Consistently high recovery was observed, with no matrix effect and a lower limit of quantitation of 5 ng/ml. Conclusion: A novel method for analyzing SRA737 in human plasma has been validated and is now being utilized for quantification of SRA737 in a Phase I trial.
Author(s): Zangarini M, Berry P, Sludden J, Raynaud FI, Banerji U, Jones P, Edwards D, Veal GJ
Publication type: Article
Publication status: Published
Print publication date: 01/07/2017
Online publication date: 10/07/2017
Acceptance date: 02/04/2016
Date deposited: 21/09/2017
ISSN (print): 1757-6180
ISSN (electronic): 1757-6199
Publisher: Future Medicine Ltd.
Altmetrics provided by Altmetric